Goldman, Jonathan W.
Rosen, Lee S.
Tolcher, Anthony W.
Papadopoulos, Kyriakos
Beeram, Muralidhar
Shi, Peipei
Pitou, Celine
Bell, Robert
Kulanthaivel, Palaniappan
Zhang, Xuekui
Fink, Aaron
Chan, Edward M.
Shahir, Ashwin
Farrington, Daphne
Patnaik, Amita
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 22 August 2017
Accepted: 23 October 2017
First Online: 1 December 2017
Compliance with ethical standards
:
: At the time the research was performed, Jonathan Goldman received research funding and consulting fees from Eli Lilly & Company. The following authors were employees and/or stockholders at Eli Lilly & Company: Palaniappan Kulanthaivel, Ashwin Shahir, Aaron Fink, Celine Pitou, Xuekui Zhang, Edward Chan, Aaron Fink, Xuekui Zhang, and Daphne Farrington. Anthony Tolcher has served on the following advisory and consulting boards: Astex, Bayer, BioInvent, Boehringer-Ingelheim, Celldex, EMD Serono, Ignyta, Johnson & Johnson, Janssen, Median, Merus, Nanobiotix, New B Innovation, Pierre Fabre, Symphogen, Zymeworks, and fees for consulting and board; memberships are paid to South Texas Accelerated Research Therapeutics for which he is a co-owner. Amita Patnaik and Murali Beeram both received institutional research funding from Eli Lilly & Company; Lee Rosen, Kyriakos Papadopoulos, Rob Bell, and Peipei Shi declare that he/she has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.